Sector News

Valeant’s still in the deal hunt, but it can grow 10%-plus without them, CEO says

January 8, 2015
Life sciences
In the wake of Valeant’s Allergan bid failure, rumors swirled that the serial buyer would swear off its modus operandi for a while to focus on cutting down debt. But according to CEO J. Michael Pearson, those who expect Valeant to stray from its dealmaking ways have another thing coming.
 
The company’s “business development activities will remain the priority for 2015,” he told investors on a conference call Thursday, noting that the Canadian pharma expects a “steady flow of small and medium-sized deals” to continue over the course of the year. It’s continuing to evaluate larger transactions, too, but the timing of those “remains difficult to predict.”
 
Still, the Quebec-based pharma is doing its best to convince its shareholders–and potential takeover targets–that it’s self-sufficient. After a months-long attack from Allergan on its business model and comparatively paltry R&D activities, Pearson Thursday touted Valeant’s pipeline and organic growth, which he expects to see climb to 10% to 12% this year.
 
Revenue from new products–which Pearson plans to promote aggressively–should help Valeant generate a top-line haul ranging between $9.2 billion and $9.3 billion, the pharma figures. Cash earnings will hit between $10.10 and $10.40 per share, it predicts.
 
In the meantime, Pearson’s putting his money where his mouth is. He’s extended his contract by 5 years, but going forward, he’ll do away with his base salary. His compensation will be wholly dependent on the company’s stock performance.
 
By Carly Helfand
 

Related News

March 6, 2021

Takeda takes full control of drug for rare epilepsies

Life sciences

The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones. 

March 6, 2021

Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

Life sciences

Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.

March 6, 2021

Disney teams with Philips to bring its characters to pediatric imaging

Life sciences

A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.

Send this to a friend